Ergothioneine and Stabilized Neurofilament Light Chain Level

Doses used in studies

mg/week: 75 (median 75, IQR 75–75) — 1 study

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 1 study

1 of 1 paper

Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study.

2024-11-15
RCT
Journal of Alzheimer's disease : JAD 102(3)
- Yu Fung Yau
- Irwin K Cheah
- Rathi Mahendran
- Richard My Tang
- Ru Yuan Chua
- Rachel Es Goh
- Lei Feng
- Jialiang Li
- Ee Heok Kua
- Christopher Chen
- Barry Halliwell

PubMed: 39544014
DOI: 10.1177/13872877241291253

2 Insights on

Stabilized Neurofilament Light Chain Level

High evidence
Clinical

stabilized plasma levels of neurofilament light chain, compared with the placebo group, which saw no improvement in cognitive assessments and a significant increase in neurofilament light chain levels

Effect: Beneficial
Effect size: Moderate
Dose: 25 mg per capsule, taken 3 times a week for one year